World’s First Database for Advanced Cutaneous Squamous Cell Carcinoma
Researchers at the Erasmus MC Cancer Institute have developed a nationwide database containing a wealth of information on cutaneous squamous cell carcinoma (CSCC). This resource will soon enable doctors to provide more personalized treatments for patients with this type of skin cancer.
New mechanism in BRCA2 tumors discovered: why chemotherapy sometimes fails
Why do some BRCA2 tumors eventually stop responding to chemotherapy? Researchers at Erasmus MC discovered how these tumors are still able to repair their DNA damage and how they evade the effects of chemotherapy.
New Erasmus MC Subsidiary Develops Personalized Immunotherapy
Erasmus MC has established a new company dedicated to developing a new form of immunotherapy. This new therapy — a personalized cancer vaccine — is intended for patients with pancreatic cancer.
European grants for research into stomach cancer and motor control
Neuroscientist Zhenyu Gao and molecular geneticist Miao-Ping Chien from Erasmus MC have been awarded Consolidator Grants from the European Research Council. They will use this 2 million euro grant for research into difficult-to-treat stomach cancer and the brain’s control of movement.
Discovery of new target in aggressive breast cancer opens door for new immunotherapy
Researchers from Erasmus MC have found a novel target for immunotherapy for an aggressive form of breast cancer. They isolated a receptor from white blood cells that recognizes the target and took the first steps towards a clinical treatment. “It was like searching for a needle in a haystack.”
Researchers break dogma: intestinal tumor does not always arise from stem cell
Scientists at Erasmus MC have discovered that intestinal tumors do not always originate from stem cells, contrary to the prevailing dogma. In the context of inflammation, specialized intestinal cells appear to be the origin of cancer.
